View allAll Photos Tagged allergan
Link: vimeo.com/659274036
Sneak Peak from our latest Campaign for Allergan Aesthetics, an Abbvie Company
www.cayetanogonzalez.com | Instagram
No natural light here, all shot with ARRI lighting.
Dir/Dop: Cayetano González @aboutlight_
Talent: Sandra T @sandra__tee - @mihamodelmanagement
Music: Sergio Díaz De Rojas @bonjoursergio
Client: Allergan Aesthetics (Peyman Azhari, Edyta Kotawicz)
Prod: Tobias Faust
1AC: Martin Bethge
2AC: Eric Gräning
DIT: John Braun
Gaffer: Brian Putkkuri
Spark: Jan Nemecky
Art Dir: Claudia König
Art Assist: Moritz Gätjens
Actresses Angie Harmom, (Latisse spokes model) Brooke Shields, and Debra Messing at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Today's news:
"Cambrian Biopharma today announced the closing of an oversubscribed Series C financing, which raised $100 million. Focused on developing therapeutics to extend healthspan, Cambrian is advancing an expansive diversified pipeline of scientific breakthroughs, each targeting a biological driver of aging that leads to disease. Their approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age.
Age-related diseases account for more than two-thirds of all deaths worldwide, taking 41 million lives every year, or nearly one death every second. Existing approaches to these diseases are almost exclusively reactive - waiting for people to get sick and only then using the rapidly expanding knowledge of biology to try to treat very sick patients.
The company also announced the appointments of Paul Farr, former Allergan chief executive, and BridgeBio director Brent Saunders to its board of directors."
• Bloomberg TV interview: "The Startup That May Hold the Key to Extending Human Life"
• CEO on twitter
• Company: www.CambrianBio.com
CONGRATS team Cambrian!
Marisa Tomei at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
The allergan breast implant attorney at Cowper Law LLP are former defense attorneys with a deep knowledge of breast implant lawsuit, medical devices, FDA law, and products liability. The firm also has a passion for issues facing women (and we currently represent 600+ women in the Essure permanent sterility device litigation where we are one of five law firms sitting on the Plaintiffs’ Steering Committee).
My Official Website:- https://cowperlaw.com/
Address:- 10880 Wilshire Blvd.Suite 1840, Los Angeles, CA 90024
Phone:- 877.529.3707
The allergan breast implant lawyers at Cowper Law LLP are former defense attorneys with a deep knowledge of breast implant lawsuit, medical devices, FDA law, and products liability. The firm also has a passion for issues facing women (and we currently represent 600+ women in the Essure permanent sterility device litigation where we are one of five law firms sitting on the Plaintiffs’ Steering Committee).
My Official Website:- https://cowperlaw.com/
Address:- 10880 Wilshire Blvd.Suite 1840, Los Angeles, CA 90024
Phone:- 877.529.3707
from ift.tt/1uxpGpG
O que são os implantes mamários e quais as marcas de referência?
Antes de se submeter a uma mamoplastia de aumento e colocar um implante mamário, deve tentar informar-se o máximo possível. Para que a conversa com o seu Cirurgião Plástico seja mais frutuosa, leve questões preparadas após se ter informado sobre a cirurgia e os implantes que poderão vir a ser usados.
O implante mamário, ou prótese mamária, é um dispositivo médico usado na mamoplastia de aumento, colocando-se por baixo do tecido mamário (subglândular) ou por de baixo do músculo (submuscular), ou na reconstrução mamária, substituindo o tecido mamário.
Tem como objectivo dar forma à mama, tornando-a mais cheia, volumosa, firme e com projecção adequada.
Os implantes mamários são de diferentes tipos, variando no tipo de material de enchimento, na textura, na forma e no tamanho.
Tendo em conta o crescimento deste mercado são muitas as marcas de próteses mamárias existentes no mercado. Contudo nem todas as marcas são iguais e muitas não oferecem a segurança necessária para este tipo de procedimentos cirúrgicos. Ainda é recente a polémica dos implantes PIP e o transtorno que causou a muitas portuguesas.
Se está a pensar fazer uma cirurgia de mamoplastia de aumento, é importante que escolha uma clínica que utilize implantes da mais elavada qualidade. Tenho a certeza que não vai querer poupar neste ponto. Afinal de contas, os implantes vão ficar muitos anos dentro do seu corpo.
Quais são as marcas de referência dos implantes mamários?
Um dos grandes mercados de referência para as próteses mamárias é, como não podia deixar de ser os Estados Unidos da América. É lá que se consome uma parte significativa da produção mundial destes dispositivos médicos.
Existem vários modelos e várias marcas de implantes mamários, no entanto, a FDA (entidade que regula o sector do medicamento e dispositivos médicos nos EUA) apenas aprovou as empresas Allergan e Mentor.
Actualmente, os implantes de silicone aprovados, pela FDA são os seguintes:
Allergan Natrelle
Allergan Natrelle 410 (Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants)
Mentor MemoryGel
Mentor MemoryShape
Sientra’s Silicone Gel Breast Implants
Os implantes de silicone Allergan’s Natrelle 410, Sientra e os Mentor’s MemoryShape são os mais recentemente aprovados, pertencendo ao grupo dos implantes chamados “gummy bear”, por serem constituídos por um silicone mais espesso e consistente.
Se tiver alguma dúvida sobre este tema, contacte-nos através deste formulário ou deixe-nos a sua questão na zona dos comentários.
The post Implantes Mamários – Marcas aprovadas pela FDA appeared first on Blog Dra. Luísa Ramos.
Actress Perry Reeves at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Actress Debra Messing at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Izabella Miko at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Actresses Angie Harmon and Debra Messing arrive at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California. (Photo by Steve Granitz/WireImage)
Cosmopolitan Skin Care Solutions
215-925-6085
Before, during, and final results during the recommended 16 week course of Latisse.
Cosmopolitan Skin Care Solutions
215-925-6085
U.S. Senator Claire McCaskill, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee, today released the first product of her wide-ranging investigation into opioid manufacturers and distributors. “Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization” describes the emphasis Insys Therapeutics put on boosting approvals for its highly addictive fentanyl drug Subsys, even for inappropriate, off-label uses, and details an audio recording in which an Insys sales representative misidentifies herself and uses language designed to circumvent the prior authorization process.
Insurers often employ this process to prevent the overprescription and abuse of powerful and expensive drugs like Subsys. While the Food and Drug Administration has only approved Subsys for the treatment of breakthrough cancer pain—cancer pain that persists despite attempted treatment with other opioid medications—an internal document obtained by McCaskill shows that Insys lacked measures to prevent its representatives from manipulating the prior authorization process and gaining approval for Subsys treatment of non-cancer conditions like back pain, fibromyalgia and migraine headaches.
“There is extensive evidence that Insys aggressively pressured its employees and the entire medical system to increase the use of a fentanyl product during a national epidemic that was taking the lives of tens of thousands of Americans a year in order to make more money—it’s hard to imagine anything more despicable,” McCaskill said. “Their attempts to manipulate the prescription approval process for this drug appear to have been systemic, and anyone responsible for this manipulation deserves to be prosecuted.”
As part of its investigation, the minority staff received an audio recording of conversations between an Insys employee and pharmacy benefit manager representatives related to a Subsys prescription for Sarah Fuller, who later died from an alleged fentanyl overdose. This recording suggests the Insys employee in question repeatedly misled Envision Pharmaceutical Services to obtain approval for Ms. Fuller’s Subsys treatment—heavily implying she was employed by the prescribing physician and misrepresenting the type of pain the patient was experiencing.
The call occurred during a period in which Insys was aggressively pressuring its employees to increase their ratio of approvals. Employees reportedly received significant financial incentives and management pressure—including quotas and group and individual bonuses—to boost the rate of Subsys authorizations. “In an internal presentation dated 2012 and entitled, “2013 SUBSYS Brand Plan,” Insys identified one of six “key strategic imperatives” as “Mitigate Prior Authorization barriers,” the report notes. “On a later slide, the company identified several tasks associated with this effort, including “Build internal [prior authorization] assistance infrastructure,” “Establish an internal 1-800 reimbursement assistance hotline,” and “Educate field force on [prior authorization] process and facilitation.”
Subsys—a fentanyl sublingual spray product approved by the Food and Drug Administration in 2012 to treat breakthrough cancer pain—can cost over $20,000 per month, and proved incredibly successful financially after its introduction to the market. Insys had “the best-performing initial public offering in 2013,” and, over the next two years, revenues tripled and profits rose 45%. The value of company stock increased 296% between 2013 and 2016.
McCaskill has previously requested information related to sales and marketing materials, internal addiction studies, details on compliance with government settlements and donations to third party advocacy groups from major opioid manufacturers. She recently expanded her investigation, requesting documents and information from opioid manufacturers Mallinckrodt, Endo, Teva, and Allergan, while a request to McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc., focused on their distribution of opioid products.
When McCaskill was ranking member of the Permanent Subcommittee on Investigations, she joined Subcommittee Chairman Rob Portman to launch an investigation into the role Medicare Part D entities, private insurers, and pharmacy benefit managers play in detecting, reporting, and addressing opioid abuse, resulting in the in-depth report, “Combatting the Opioid Epidemic: A Review of Anti-Abuse Efforts in Medicare and Private Health Insurance Systems.”
Visit www.mccaskill.senate.gov/opioid-investigation to learn more about McCaskill’s investigation.
Famous eye-brow expert Anastasia Soare at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Actress Skye Neller at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
Photo – DRURY BRENNAN/patrickmcmullan.com
U.S. Senator Claire McCaskill, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee, today released the first product of her wide-ranging investigation into opioid manufacturers and distributors. “Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization” describes the emphasis Insys Therapeutics put on boosting approvals for its highly addictive fentanyl drug Subsys, even for inappropriate, off-label uses, and details an audio recording in which an Insys sales representative misidentifies herself and uses language designed to circumvent the prior authorization process.
Insurers often employ this process to prevent the overprescription and abuse of powerful and expensive drugs like Subsys. While the Food and Drug Administration has only approved Subsys for the treatment of breakthrough cancer pain—cancer pain that persists despite attempted treatment with other opioid medications—an internal document obtained by McCaskill shows that Insys lacked measures to prevent its representatives from manipulating the prior authorization process and gaining approval for Subsys treatment of non-cancer conditions like back pain, fibromyalgia and migraine headaches.
“There is extensive evidence that Insys aggressively pressured its employees and the entire medical system to increase the use of a fentanyl product during a national epidemic that was taking the lives of tens of thousands of Americans a year in order to make more money—it’s hard to imagine anything more despicable,” McCaskill said. “Their attempts to manipulate the prescription approval process for this drug appear to have been systemic, and anyone responsible for this manipulation deserves to be prosecuted.”
As part of its investigation, the minority staff received an audio recording of conversations between an Insys employee and pharmacy benefit manager representatives related to a Subsys prescription for Sarah Fuller, who later died from an alleged fentanyl overdose. This recording suggests the Insys employee in question repeatedly misled Envision Pharmaceutical Services to obtain approval for Ms. Fuller’s Subsys treatment—heavily implying she was employed by the prescribing physician and misrepresenting the type of pain the patient was experiencing.
The call occurred during a period in which Insys was aggressively pressuring its employees to increase their ratio of approvals. Employees reportedly received significant financial incentives and management pressure—including quotas and group and individual bonuses—to boost the rate of Subsys authorizations. “In an internal presentation dated 2012 and entitled, “2013 SUBSYS Brand Plan,” Insys identified one of six “key strategic imperatives” as “Mitigate Prior Authorization barriers,” the report notes. “On a later slide, the company identified several tasks associated with this effort, including “Build internal [prior authorization] assistance infrastructure,” “Establish an internal 1-800 reimbursement assistance hotline,” and “Educate field force on [prior authorization] process and facilitation.”
Subsys—a fentanyl sublingual spray product approved by the Food and Drug Administration in 2012 to treat breakthrough cancer pain—can cost over $20,000 per month, and proved incredibly successful financially after its introduction to the market. Insys had “the best-performing initial public offering in 2013,” and, over the next two years, revenues tripled and profits rose 45%. The value of company stock increased 296% between 2013 and 2016.
McCaskill has previously requested information related to sales and marketing materials, internal addiction studies, details on compliance with government settlements and donations to third party advocacy groups from major opioid manufacturers. She recently expanded her investigation, requesting documents and information from opioid manufacturers Mallinckrodt, Endo, Teva, and Allergan, while a request to McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc., focused on their distribution of opioid products.
When McCaskill was ranking member of the Permanent Subcommittee on Investigations, she joined Subcommittee Chairman Rob Portman to launch an investigation into the role Medicare Part D entities, private insurers, and pharmacy benefit managers play in detecting, reporting, and addressing opioid abuse, resulting in the in-depth report, “Combatting the Opioid Epidemic: A Review of Anti-Abuse Efforts in Medicare and Private Health Insurance Systems.”
Visit www.mccaskill.senate.gov/opioid-investigation to learn more about McCaskill’s investigation.
Lori, a makeup artist in Chicago, IL discusses her experience with using facial filler treatments by Dr. Anil Shah, to look more youthful, see less deep lines and wrinkles, and take the years off!
via WordPress ift.tt/16RBpoF
Richmond Plastic Surgeons l Rhinoplasty l Laser Hair Removal l Botox Richmond VA
Top Rated Richmond Plastic Surgeon (757)272-1336, ear nose and throat doctor, specializing in laser hair removal, rhinoplasty, facelifts, brow lift, eyelid surgery and chin implants.
Dr. Shaw is Richmond's facial plastic and reconstructive expert. Take the pure approach to rejuvenation with Dr. Shaw’s minimally invasive technique for looking your best by highlighting the natural you. He provides the newest and most minimally invasive facial rejuvenation that restores your skin to its original splendor, leaving no evidence that work has been done. He calls it The Natural Look.
At the core of The Natural Look rests a focus on drawing attention to your eyes, enabling them to communicate vitality, health, and wellness. Dr. Shaw takes a personal approach to each patient, carefully analyzing different features of the face and applying his artistic eye and scientific concepts to put together a customized treatment plan in order to maximize your most attractive features and highlight your natural beauty.
Dr. Travis Shaw has extensive experience working with the face from his background as a head and neck surgeon and is uniquely qualified as one of only 1000 surgeons certified by the American Board of Otolaryngology Head and Neck Surgery and the American Board of Facial, Plastic and Reconstructive Surgery.
He has performed thousands of surgical cases involving facial trauma, complex reconstruction and cosmetic surgery rejuvenation and is one of the region’s only Botox and Juvederm instructors certified by Allergan, Inc., the parent company of Botox.
Dr Travis Shaw obtained his BA in East Asian studies from Washington and Lee University. He spent two and a half years teaching English in Japan before pursuing graduate studies at the University of Virginia. Dr. Shaw completed medical school and his residency training at VCU’s Medical College of Virginia.
Dr. Shaw is board certified by the American Board of Otolaryngology and the American Board of Facial Plastic and Reconstructive Surgery.
Philanthropy has been a strong force in Dr. Shaw’s life before deciding to become a physician, and now is a cornerstone of his current practice.
Dr. Shaw’s father is a physician in Newport News, Va. and instilled in his son a deep sense of responsibility to care for others. The senior Dr. James Shaw donated his time on medical missions to the Ukraine and the Dominican Republic before founding the Lackey Free Medical Clinic near Yorktown. The senior Dr. Shaw started the faith based clinic in the back room of a church on Thursday nights and watched it grow into one of the largest free clinics in the state, delivering over 5.8 million dollars in free care last year to those in need.
In his second year in Medical school Dr Travis Shaw set out with his father to Kjabe Hospital in Kenya. During this trip, he witnessed many patients who had facial deformities.
While a resident at MCV, Dr. Shaw was a part of a cleft lip and palate mission to Belize as part of the World Pediatric Project Their team of four surgeons spent a week operating on children with cleft lip and palate deformities, as well as those with congenital defects of the ear.
Dr. Shaw performs free reconstructive surgery on domestic violence victims through the program Face To Face.
Dr. Shaw has been recognized in Richmond as a Top Plastic Surgeon in the areas of rhinoplasty, facelift surgery, eyelid surgery, and brow lift surgery.
Travis Shaw, MD
8730 Stony Point Parkway
Suite 120
Richmond, Virginia 23235
(757)272-1336
Find plastic surgeons in local areas throughout the U.S. here: ift.tt/1EP8yzP
More plastic surgery videos:
From:Find Best Plastic Surgeons
Views:
2
0ratings
Time:00:52
More inHowto & Style
Watch video on YouTube here: ift.tt/1IPQVmn
via U.S. Top Board Certified Local Surgeons
Lori, a makeup artist in Chicago, IL discusses her experience with using facial filler treatments by Dr. Anil Shah, to look more youthful, see less deep lines and wrinkles, and take the years off!
U.S. Senator Claire McCaskill, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee, today released the first product of her wide-ranging investigation into opioid manufacturers and distributors. “Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization” describes the emphasis Insys Therapeutics put on boosting approvals for its highly addictive fentanyl drug Subsys, even for inappropriate, off-label uses, and details an audio recording in which an Insys sales representative misidentifies herself and uses language designed to circumvent the prior authorization process.
Insurers often employ this process to prevent the overprescription and abuse of powerful and expensive drugs like Subsys. While the Food and Drug Administration has only approved Subsys for the treatment of breakthrough cancer pain—cancer pain that persists despite attempted treatment with other opioid medications—an internal document obtained by McCaskill shows that Insys lacked measures to prevent its representatives from manipulating the prior authorization process and gaining approval for Subsys treatment of non-cancer conditions like back pain, fibromyalgia and migraine headaches.
“There is extensive evidence that Insys aggressively pressured its employees and the entire medical system to increase the use of a fentanyl product during a national epidemic that was taking the lives of tens of thousands of Americans a year in order to make more money—it’s hard to imagine anything more despicable,” McCaskill said. “Their attempts to manipulate the prescription approval process for this drug appear to have been systemic, and anyone responsible for this manipulation deserves to be prosecuted.”
As part of its investigation, the minority staff received an audio recording of conversations between an Insys employee and pharmacy benefit manager representatives related to a Subsys prescription for Sarah Fuller, who later died from an alleged fentanyl overdose. This recording suggests the Insys employee in question repeatedly misled Envision Pharmaceutical Services to obtain approval for Ms. Fuller’s Subsys treatment—heavily implying she was employed by the prescribing physician and misrepresenting the type of pain the patient was experiencing.
The call occurred during a period in which Insys was aggressively pressuring its employees to increase their ratio of approvals. Employees reportedly received significant financial incentives and management pressure—including quotas and group and individual bonuses—to boost the rate of Subsys authorizations. “In an internal presentation dated 2012 and entitled, “2013 SUBSYS Brand Plan,” Insys identified one of six “key strategic imperatives” as “Mitigate Prior Authorization barriers,” the report notes. “On a later slide, the company identified several tasks associated with this effort, including “Build internal [prior authorization] assistance infrastructure,” “Establish an internal 1-800 reimbursement assistance hotline,” and “Educate field force on [prior authorization] process and facilitation.”
Subsys—a fentanyl sublingual spray product approved by the Food and Drug Administration in 2012 to treat breakthrough cancer pain—can cost over $20,000 per month, and proved incredibly successful financially after its introduction to the market. Insys had “the best-performing initial public offering in 2013,” and, over the next two years, revenues tripled and profits rose 45%. The value of company stock increased 296% between 2013 and 2016.
McCaskill has previously requested information related to sales and marketing materials, internal addiction studies, details on compliance with government settlements and donations to third party advocacy groups from major opioid manufacturers. She recently expanded her investigation, requesting documents and information from opioid manufacturers Mallinckrodt, Endo, Teva, and Allergan, while a request to McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc., focused on their distribution of opioid products.
When McCaskill was ranking member of the Permanent Subcommittee on Investigations, she joined Subcommittee Chairman Rob Portman to launch an investigation into the role Medicare Part D entities, private insurers, and pharmacy benefit managers play in detecting, reporting, and addressing opioid abuse, resulting in the in-depth report, “Combatting the Opioid Epidemic: A Review of Anti-Abuse Efforts in Medicare and Private Health Insurance Systems.”
Visit www.mccaskill.senate.gov/opioid-investigation to learn more about McCaskill’s investigation.
inagorillacostume.com/2011/botox-guerrilla-marketing-pois...
The company, Allergan Inc. of Irvine, announced last month that the Food and Drug Administration approved its new method to test Botox's potency. Instead of having to test every batch on live animals, it can now run a test on cells in a lab dish.
[caption id="attachment_1769" align="aligncenter" width="600" caption="Botox Guerrilla Marketing Poisened Animals to Reduce Animal Testing"] [/caption]
Since the news, Allergan Inc. has been taking it to the streets in an intriguing, larger-than-life guerrilla marketing series which features a dead mouse on the side of the street next to a toxic bottle. The company and somewhat disturbing guerrilla marketing campaign hopes the effort will reduce poisened animal testing.
Apparently, it took 10 years for Allergan scientists to perfect the new test and if it's approved in all the countries where Botox is sold, Allergan expects to eliminate the need for at least 95% of its animal testing within three years.
Check out the original article posted on the LA Times. It has some really interesting facts and stats such as the ones I've quoted below.
Labs in the United States use nearly 1 million mammals per year, according to 2009 statistics from the U.S. Department of Agriculture. However, that number excludes mice and rats — the most popular laboratory workhorses — because the U.S. Animal Welfare Act does not cover them. In a 2008 article in the journal Alternatives to Laboratory Animals, a group of animal activists estimated that the total number of research animals used in the U.S. is closer to 17 million, including rodents, birds, reptiles, amphibians and fish.
For their new test, Allergan scientists grow nerve cells in a dish. Then they squirt in different doses from their latest batch of Botox and check the neurotransmitter-pumping protein after a few days to see how much of it is cut versus whole. The entire test takes about a week.
[ad#Google Adsense - 468 x 60]
Latisse spoke-model Brooke Shields at the Launch Party For LATISSE on March 26, 2009 in Los Angeles, California.
Cosmopolitan Skin Care Solutions
215-925-6085
U.S. Senator Claire McCaskill, the top-ranking Democrat on the Senate Homeland Security and Governmental Affairs Committee, today released the first product of her wide-ranging investigation into opioid manufacturers and distributors. “Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulation of Prior Authorization” describes the emphasis Insys Therapeutics put on boosting approvals for its highly addictive fentanyl drug Subsys, even for inappropriate, off-label uses, and details an audio recording in which an Insys sales representative misidentifies herself and uses language designed to circumvent the prior authorization process.
Insurers often employ this process to prevent the overprescription and abuse of powerful and expensive drugs like Subsys. While the Food and Drug Administration has only approved Subsys for the treatment of breakthrough cancer pain—cancer pain that persists despite attempted treatment with other opioid medications—an internal document obtained by McCaskill shows that Insys lacked measures to prevent its representatives from manipulating the prior authorization process and gaining approval for Subsys treatment of non-cancer conditions like back pain, fibromyalgia and migraine headaches.
“There is extensive evidence that Insys aggressively pressured its employees and the entire medical system to increase the use of a fentanyl product during a national epidemic that was taking the lives of tens of thousands of Americans a year in order to make more money—it’s hard to imagine anything more despicable,” McCaskill said. “Their attempts to manipulate the prescription approval process for this drug appear to have been systemic, and anyone responsible for this manipulation deserves to be prosecuted.”
As part of its investigation, the minority staff received an audio recording of conversations between an Insys employee and pharmacy benefit manager representatives related to a Subsys prescription for Sarah Fuller, who later died from an alleged fentanyl overdose. This recording suggests the Insys employee in question repeatedly misled Envision Pharmaceutical Services to obtain approval for Ms. Fuller’s Subsys treatment—heavily implying she was employed by the prescribing physician and misrepresenting the type of pain the patient was experiencing.
The call occurred during a period in which Insys was aggressively pressuring its employees to increase their ratio of approvals. Employees reportedly received significant financial incentives and management pressure—including quotas and group and individual bonuses—to boost the rate of Subsys authorizations. “In an internal presentation dated 2012 and entitled, “2013 SUBSYS Brand Plan,” Insys identified one of six “key strategic imperatives” as “Mitigate Prior Authorization barriers,” the report notes. “On a later slide, the company identified several tasks associated with this effort, including “Build internal [prior authorization] assistance infrastructure,” “Establish an internal 1-800 reimbursement assistance hotline,” and “Educate field force on [prior authorization] process and facilitation.”
Subsys—a fentanyl sublingual spray product approved by the Food and Drug Administration in 2012 to treat breakthrough cancer pain—can cost over $20,000 per month, and proved incredibly successful financially after its introduction to the market. Insys had “the best-performing initial public offering in 2013,” and, over the next two years, revenues tripled and profits rose 45%. The value of company stock increased 296% between 2013 and 2016.
McCaskill has previously requested information related to sales and marketing materials, internal addiction studies, details on compliance with government settlements and donations to third party advocacy groups from major opioid manufacturers. She recently expanded her investigation, requesting documents and information from opioid manufacturers Mallinckrodt, Endo, Teva, and Allergan, while a request to McKesson Corporation, AmerisourceBergen Corporation, and Cardinal Health, Inc., focused on their distribution of opioid products.
When McCaskill was ranking member of the Permanent Subcommittee on Investigations, she joined Subcommittee Chairman Rob Portman to launch an investigation into the role Medicare Part D entities, private insurers, and pharmacy benefit managers play in detecting, reporting, and addressing opioid abuse, resulting in the in-depth report, “Combatting the Opioid Epidemic: A Review of Anti-Abuse Efforts in Medicare and Private Health Insurance Systems.”
Visit www.mccaskill.senate.gov/opioid-investigation to learn more about McCaskill’s investigation.
"How the Pfizer-Allergan Deal Ranks" by LESLIE PICKER via NYT t.co/gkcYSjKjC8 (via Twitter twitter.com/felipemassone/status/668864658447671296)